AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.
AusperBio has raised $63.0M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
AusperBio's investors include Qiming Venture Partners, CDH Investments, BioVenture, Sherpa Healthcare Partners, Genesis Capital.
AusperBio is headquartered in Foster City, United States.
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.
AusperBio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AusperBio — Funding & Investors." VCBacked, September 21, 2025, https://www.vcbacked.co/company/ausperbio. Accessed July 20, 2026.
VCBacked. (2025). AusperBio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ausperbio
{{cite web |title=AusperBio — Funding & Investors |url=https://www.vcbacked.co/company/ausperbio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated